Secondary tabs
Contact details
Heleen van Engeland
Main
Ron Herings
Alternate
Publications
Data source publications
- Houweling LM, Bezemer ID, Penning-van Beest FJ, Meijer WM, van Lingen RA, Herings RM. First Year of Life Medication Use and Hospital Admission Rates: Premature Compared with Term Infants. The Journal of pediatrics. 2013163(1):61-66.
- Kuiper, Josephina G., et al. "A population‐based linked cohort of cancer and primary care data: A new source to study the management of cancer in primary care." European Journal of Cancer Care 31.1 (2022): e13529.
- Houben, Eline, et al. "Cohort profile: The PHARMO Perinatal Research Network (PPRN) in the Netherlands: A population-based mother–child linked cohort." BMJ open 10.9 (2020): e037837.
- Kuiper, Josephina G., et al. "Existing data sources for clinical epidemiology: the PHARMO database network." Clinical Epidemiology (2020): 415-422.
- Overbeek, Jetty A., et al. "Completeness and Representativeness of the PHARMO General Practitioner (GP) Data: A Comparison with National Statistics." Clinical Epidemiology (2022): 1-11.
Studies
List of studies that have been conducted using the data source
- Real-world effectiveness of extrafine vesrus standard particle inhaled corticosteroids: A comparative effectiveness analysis of extrafine (EF) hydrofluoroalkane beclometasone (HFA-BDP) and Ciclesonide versus commonly prescribed standard particle inhaled corticosteroids for patients prescribed asthma therapy in The Netherlands (Extrafine vesrus stand particle ICS effectiveness)
- POST-APPROVAL SAFETY STUDY (PASS) OF THE UTILIZATION PATTERN OF APIXABAN IN THE NETHERLANDS
- An Observational Post-Authorization Safety Study (PASS) of MOVENTIG® (Naloxegol) Among Patients Aged 18 Years and Older Treated with Opioids Chronically
- Evaluation of the Use of Nepafenac in Selected European Populations
- Safety Evaluation of Adverse Reactions in Diabetes - Drug utilisation studies (SAFEGUARD)
- Identification of type 2 diabetes cases in a set of databases participating to the EMIF project
- A multinational active safety surveillance study of crizotinib in Europe and the United States
- Real-world effectiveness of extra-fine Ciclesonide (Alvesco®) versus standard particle inhaled corticosteroid (ICS)
- A non-interventional post-authorisation safety study (PASS) of vortioxetine in Europe
- EMIF Use Case 17 - Investigating the relationship in paediatric population between dosing of antibiotics (prescribed, dispensed or administered) and patient’s weight. (EMIF UC17)
- Estimating prevalence and incidence of acute myocardial infarction in a set of heterogeneous sources of observational health data collaborating in the EMIF Platform
- A PHARMO Study on the Utilization of Pioglitazone in Clinical Practice in The Netherlands with Regard to Diabetic Treatment Regimen and Co-morbidities
- Drug utilization study of mirabegron (Betmiga®) using real-world healthcare databases from the Netherlands, Spain, United Kingdom and Finland (Mirabegron DUS)
- Drug utilization study of cyproterone/ethinylestradiol (Diane®-35 and generics) in the Netherlands, UK and Italy
- Adherence, persistence and switching patterns – once- and twice-daily direct oral anticoagulants (QD versus BID DOACs)
- Drug Utilisation Study for Olodaterol
- Impact of EU label changes for systemic diclofenac products: post-referral prescribing trends
- A Retrospective Cohort Study to Assess Drug Utilisation and Long-Term Safety of Galcanezumab in European Patients in the Course of Routine Clinical Care (I5Q-MC-B002)
- Drug-drug interactions between dicloxacillin/flucloxacillin and DOACs
- Impact of EU label changes for hydroxyzine products: post-referral prescribing trends
- The relationship between the month of birth and ADHD treatment
- Intravenous Iron Postauthorisation Safety Study (PASS): Evaluation of the Risk of Severe Hypersensitivity Reactions
- A pharmacoepidemiological study of Rivaroxaban use and potential adverse outcomes in routine clinical pratice in the Netherlands
- The BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study in electronic healthcare databases
- Dulaglutide Modified-Prescription-Event Monitoring Study and network database study: a multi-database collaborative research program of observational studies to monitor the utilisation and safety of dulaglutide in the EU
- Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus, Pimecrolimus, and Corticosteroids: Protopic JOint European Longitudinal Lymphoma and skin cancer Evaluation (JOELLE) Study
- Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus, Pimecrolimus, and Corticosteroids (JOELLE)
- Post Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
- A Post-Authorisation Safety Study of the Utilisation and Prescribing Patterns of Xeljanz® (tofacitinib) in the European Union Using Secondary Data Sources
- Post-Authorisation Active Surveillance Study of Myocarditis and Pericarditis Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
- Utilisation of low-dose rivaroxaban in patients with atherosclerotic cardiovascular disease in the united kingdom and the netherlands
- A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources (COVID-19)
- Non-interventional post-authorization multi-database safety study to characterize the risk of angioedema and other specific safety events of interest in association with use of Entresto® (sacubitril/valsartan) in adult patients with heart failure
- An Observational Post-Authorization Safety Study to Assess the Safety of Ad26.COV2.S Using European Healthcare Data through VAC4EU (COVID-19)
- A Drug Utilisation Study extension (DUS ext.) of valproate and related substances, in Europe, using databases (VALNAC09343)
- Non-interventional post-authorization multi-database safety study to assess the risk of myotoxicity, hepatotoxicity and acute pancreatitis in statin-exposed heart failure patients with or without concomitant use of sacubitril/valsartan (Entresto®)
- FINErenone druG Utilization Study and assessment of Temporal changes following availability of different treatment options in patients with chronic kidney disease and type 2 diabetes (FINEGUST)
- Strengthening Use of Real-World Data in Medicines Development: Metadata for Data Discoverability and Study Replicability (MINERVA)
- Comparison of the Risk of Cancer Between Patients With Type 2 Diabetes Exposed to Dapagliflozin and Those Exposed to Other Antidiabetic Treatments
- Concordance between primary and secondary electronic healthcare databases: A multi-database self-controlled case series study
- Impact of EU label changes and revised pregnancy prevention programme for oral retinoid containing medicinal products: utilization and prescribing trends
- Impact of EU label changes and revised pregnancy prevention programme for medicinal products containing valproate: utilisation and prescribing trends
- Effectiveness of heterologous and booster Covid-19 vaccination in 5 European countries, using a cohort approach in children and adults with a full primary Covid-19 vaccination regimen (Covid Vaccines Effectiveness (CoVE))
- Cohort monitoring of Adverse Events of Special Interest and COVID-19 diagnoses prior to and after COVID-19 vaccination (ECVM)
- Rapid Safety Assessment of SARS-CoV-2 vaccines in EU Member States using electronic health care datasources (CVM Covid19-Vaccine-Monitor-EHR)
- Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines (ACCESS-BGR)
- Baricitinib Drug Utilisation Study: Assessment of Effectiveness of New Recommendations for Use Based on Secondary Data Sources in France, Germany, The Netherlands, and Sweden (I4V-MC-B038)
- Post-authorisation Safety Study of Rimegepant in Patients with Migraine and History of Cardiovascular Disease in European Countries
- The Impact of COVID-19 Pandemic on Drug Use: Implications for Regulatory Intervention Impact Studies
- Characterization of neurodevelopmental disorders in children exposed in utero to valproate and/or other antiepileptic drugs with long-term follow-up: retrospective study of multiple European data sources (AVALON)
- Post-Authorisation Safety Study of Comirnaty Original/Omicron BA.1 and Comirnaty Original/Omicron BA.4-5 in Europe
- Long-term real-world safety of ozanimod – A post-authorisation safety study (PASS) in patients diagnosed with ulcerative colitis
- A real-world observational study of treatment patterns and outcomes for patients with neuromyelitis optica spectrum disorders (NMOSD) treated with inebilizumab (UPLIZNA) in Europe
- ADEPT: The utilisation of antiseizure medications in pregnant women, other women of childbearing potential, and men: a multi-database study from 7 European countries
- ADEPT: feasibility of estimating the risk of adverse pregnancy, neonatal and child outcomes following either in utero ASM exposure through the mother, or peri-conceptional ASM exposure through the father
- A Post-Authorisation Safety Study (PASS) of ABRYSVO (Respiratory Syncytial Virus Stabilised Prefusion Subunit Vaccine) in Pregnant Women and their Offspring in a Real World Setting in Europe and UK